{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:52:21Z","timestamp":1791298341186,"version":"4.1.0"},"reference-count":322,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":1621,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1016\/j.bbmt.2010.08.001","type":"journal-article","created":{"date-parts":[[2010,8,11]],"date-time":"2010-08-11T05:12:40Z","timestamp":1281503560000},"page":"1467-1503","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":123,"title":["NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation"],"prefix":"10.1016","volume":"16","author":[{"given":"David L.","family":"Porter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin P.","family":"Alyea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph H.","family":"Antin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"DeLima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli","family":"Estey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.H. Frederik","family":"Falkenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaus","family":"Kroeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Leis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Maloney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Peggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob M.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan S.","family":"Wayne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"van Besien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2010.08.001_bib1","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.bbmt.2010.03.002","volume":"16","author":"Cairo","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib2","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","article-title":"Graft-versus-leukemia reactions after bone marrow transplantation","volume":"75","author":"Horowitz","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib3","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1182\/blood.V76.12.2462.2462","article-title":"Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients","volume":"76","author":"Kolb","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib4","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.1997.15.2.433","article-title":"Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation","volume":"15","author":"Collins","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib5","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1056\/NEJM199401133300204","article-title":"Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia","volume":"330","author":"Porter","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2010.08.001_bib6","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1182\/blood.V94.4.1201","article-title":"Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes","volume":"94","author":"Falkenburg","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib7","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1038\/sj.leu.2404169","article-title":"Molecular persistence of chronic myeloid leukemia caused by donor T cells specific for lineage-restricted maturation antigens not recognizing immature progenitor-cells","volume":"20","author":"von dem Borne","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.08.001_bib8","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0301-472X(03)00190-5","article-title":"Minor histocompatibility antigens in human stem cell transplantation","volume":"31","author":"Falkenburg","year":"2003","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib9","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1073\/pnas.0530192100","article-title":"Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia","volume":"100","author":"Marijt","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bbmt.2010.08.001_bib10","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1182\/blood-2004-09-3660","article-title":"Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission","volume":"105","author":"Miklos","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib11","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1182\/blood.V86.4.1261.bloodjournal8641261","article-title":"Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease","volume":"86","author":"Mackinnon","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib12","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood.V100.2.397","article-title":"Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose","volume":"100","author":"Guglielmi","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib13","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/bmt.2009.177","article-title":"Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the Chronic Leukemia Working Party of the EBMT","volume":"45","author":"Chalandon","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib14","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1182\/blood.V96.8.2712","article-title":"Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia","volume":"96","author":"Dazzi","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib15","first-page":"1214","article-title":"Treatment of relap sed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions","volume":"95","author":"Porter","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib16","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1080\/10428190600632857","article-title":"Extramedullary sites of leukemia relapse after transplant","volume":"47","author":"Cunningham","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2010.08.001_bib17","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/10428190902755513","article-title":"Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation","volume":"50","author":"Ocheni","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2010.08.001_bib18","first-page":"391","article-title":"Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression","volume":"10","author":"Collins","year":"1992","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib19","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/01.TP.0000111759.48240.F5","article-title":"Effect of FK506 on donor T-cell functions that are responsible for graft-versus-host disease and graft-versus-leukemia effect","volume":"77","author":"Imado","year":"2004","journal-title":"Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib20","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1182\/blood-2008-02-141689","article-title":"Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia","volume":"112","author":"Lee","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib21","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1182\/blood.V90.7.2549","article-title":"Use of alpha-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation","volume":"90","author":"Higano","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib22","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.bbmt.2003.11.003","article-title":"Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease","volume":"10","author":"Posthuma","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib23","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.bbmt.2009.08.019","article-title":"Current status and perspectives of tyrosine kinase inhibitor treatment in the posttransplant period in patients with chronic myelogenous leukemia (CML)","volume":"16","author":"Klyuchnikov","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib24","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.bbmt.2009.11.026","article-title":"Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation","volume":"16","author":"Wright","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib25","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1182\/blood-2007-05-090340","article-title":"Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone","volume":"110","author":"Miller","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib26","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1182\/blood-2008-03-077974","article-title":"Graft-versus-leukemia effects of transplantation and donor lymphocytes","volume":"112","author":"Kolb","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib27","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1182\/blood-2009-10-248997","article-title":"Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens","volume":"115","author":"Warren","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib28","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/00062752-200211000-00006","article-title":"Overexpressed differentiation antigens as targets of graft-versus-leukemia reactions","volume":"9","author":"Molldrem","year":"2002","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib29","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.1158\/0008-5472.CAN-07-0302","article-title":"BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells","volume":"67","author":"Brauer","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2010.08.001_bib30","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2008-04-150045","article-title":"Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia","volume":"112","author":"Quintarelli","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib31","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1365-2362.2009.02206.x","article-title":"Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily","volume":"39","author":"Sillaber","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.bbmt.2010.08.001_bib32","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood-2004-07-2527","article-title":"Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner","volume":"105","author":"Seggewiss","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib33","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1056\/NEJMoa0811036","article-title":"Loss of mismatched HLA in leukemia after stem-cell transplantation","volume":"361","author":"Vago","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2010.08.001_bib34","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1158\/1078-0432.CCR-05-0036","article-title":"Graft-versus-leukemia target antigens in chronic myelogenous leukemia are expressed on myeloid progenitor cells","volume":"11","author":"Wu","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2010.08.001_bib35","first-page":"857","article-title":"Treatment with tyrosine kinase inhibitors may impair the potential curative effect of allogeneic stem cell transplantation","volume":"114","author":"Jedema","year":"2009","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.bbmt.2010.08.001_bib36","first-page":"1176","article-title":"Nilotinib treatment post-allogeneic stem cell transplantation (alloSCT) in advanced (>CP1) chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL)","volume":"114","author":"Nagler","year":"2009","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.bbmt.2010.08.001_bib37","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1182\/blood.V91.10.3671","article-title":"Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant","volume":"91","author":"Alyea","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib38","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.beha.2006.05.003","article-title":"Donor leukocyte infusions in myeloid malignancies: new strategies","volume":"19","author":"Porter","year":"2006","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib39","doi-asserted-by":"crossref","first-page":"15825","DOI":"10.1073\/pnas.0908358106","article-title":"Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation","volume":"106","author":"Ho","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bbmt.2010.08.001_bib40","author":"Kroger","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib41","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1600-0609.2008.01158.x","article-title":"Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia","volume":"82","author":"Candoni","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib42","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.exphem.2008.09.014","article-title":"Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation","volume":"37","author":"Bacher","year":"2009","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib43","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/sj.bmt.1705888","article-title":"Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant","volume":"41","author":"Shaw","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib44","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0140-6736(78)92879-9","article-title":"Remission of relapsed leukemia during a graft-versus-host reaction: a \u201cgraft-versus-leukemia\u201d reaction in man?","volume":"ii","author":"Odom","year":"1978","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2010.08.001_bib45","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1038\/sj.leu.2404828","article-title":"Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation","volume":"21","author":"Oran","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.08.001_bib46","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/sj.bmt.1705898","article-title":"Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation","volume":"41","author":"Loren","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib47","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.bbmt.2009.01.021","article-title":"Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes","volume":"15","author":"van Besien","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib48","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041","article-title":"Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia","volume":"86","author":"Kolb","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib49","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.2002.20.2.405","article-title":"Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation","volume":"20","author":"Levine","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib50","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/sj.leu.2402950","article-title":"Donor leukocyte infusions in acute myelogenous leukemia","volume":"17","author":"Porter","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.08.001_bib51","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1200\/JCO.2007.11.6053","volume":"25","author":"Schmid","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib52","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3324\/haematol.10570","article-title":"Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched\/haploidentical T-cell-replete hematopoietic stem cell transplantation","volume":"92","author":"Huang","year":"2007","journal-title":"Haematology"},{"key":"10.1016\/j.bbmt.2010.08.001_bib53","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/bmt.2008.321","article-title":"Response and toxicity of\u00a0donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6\/6 HLA matched donors","volume":"43","author":"Rizzieri","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib54","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/bmt.2008.135","article-title":"Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population","volume":"42","author":"Levine","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib55","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1083-8791(00)70057-7","article-title":"Granulocyte colony-stimulating factor given to donors before apheresis does not prevent aplasia in patients treated with donor leukocyte infusion for recurrent chronic myeloid leukemia after bone marrow transplantation","volume":"6","author":"Flowers","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib56","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/sj.bmt.1704536","article-title":"CD8+ cell depletion of donor lymphocyte infusions using cd8 monoclonal antibody-coated high-density microparticles (CD8-HDM) after allogeneic hematopoietic stem cell transplantation: a pilot study","volume":"34","author":"Alyea","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib57","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1053\/bbmt.2002.v8.abbmt080625","article-title":"Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion","volume":"8","author":"Soiffer","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib58","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1182\/blood.V86.11.4337.bloodjournal86114337","article-title":"CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation","volume":"86","author":"Giralt","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib59","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.bbmt.2007.06.007","article-title":"Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation","volume":"13","author":"Mielcarek","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib60","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1200\/JCO.1989.7.1.50","article-title":"Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy","volume":"7","author":"Mortimer","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib61","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1038\/sj.leu.2403523","article-title":"Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse","volume":"18","author":"Choi","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.08.001_bib62","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1002\/cncr.24198","article-title":"Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia","volume":"115","author":"Jabbour","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2010.08.001_bib63","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/bmt.2009.64","article-title":"Non-intensive treatment with low-dose 5-aza-2\u2032-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS\/AML patients","volume":"44","author":"Lubbert","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib64","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/bmt.2009.222","article-title":"Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting","volume":"45","author":"Lubbert","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib65","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/bmt.2008.400","article-title":"Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome","volume":"43","author":"De Padua","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib66","doi-asserted-by":"crossref","first-page":"6567","DOI":"10.1182\/blood-2009-03-208298","article-title":"Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation","volume":"113","author":"Metzelder","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib67","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1182\/blood-2002-09-2937","article-title":"New designs for phase 2 clinical trials","volume":"102","author":"Estey","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib68","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/MOH.0b013e3283257a87","article-title":"Second hematopoietic stem cell transplantation in myeloid malignancies","volume":"16","author":"Arfons","year":"2009","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib69","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/sj.bmt.1704645","article-title":"Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant","volume":"34","author":"Eapen","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib70","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.bbmt.2010.08.001_bib71","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1365-2249.2007.03360.x","article-title":"Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation","volume":"148","author":"Clausen","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib72","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1182\/blood-2008-07-171926","article-title":"Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia","volume":"113","author":"Cooley","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib73","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.bbmt.2009.01.018","article-title":"What is the role for donor natural killer cells after nonmyeloablative conditioning?","volume":"15","author":"Baron","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib74","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1537-2995.2006.01145.x","article-title":"Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience","volume":"47","author":"McKenna","year":"2007","journal-title":"Transfusion"},{"key":"10.1016\/j.bbmt.2010.08.001_bib75","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/sj.bmt.1704223","article-title":"Bone marrow vs extramedullary relapse of acute leukemia after allogeneic hematopoietic cell transplantation: risk factors and clinical course","volume":"32","author":"Lee","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib76","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1038\/leu.2008.251","article-title":"Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children\u2019s Oncology Group study","volume":"22","author":"Nguyen","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.08.001_bib77","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib78","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1200\/JCO.2001.19.16.3675","article-title":"Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation","volume":"19","author":"Bosi","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib79","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/sj.bmt.1700680","article-title":"Second allogeneic bone marrow transplantation for post-transplant leukemia relapse: results of a survey of 66 cases in 24 Japanese institutes","volume":"19","author":"Kishi","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib80","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1046\/j.1365-2141.2000.01851.x","article-title":"Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Societe Francaise de Greffe de moelle (SFGM)","volume":"108","author":"Michallet","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib81","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1182\/blood-2008-02-140095","article-title":"A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation","volume":"112","author":"Ciceri","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib82","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1365-2141.1988.tb02488.x","article-title":"Relapse after allogeneic bone marrow transplantation for acute leukaemia: a survey by the E.B.M.T. of 117 cases","volume":"70","author":"Frassoni","year":"1988","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib83","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1056\/NEJM197905103001902","article-title":"Antileukemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts","volume":"300","author":"Weiden","year":"1979","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2010.08.001_bib84","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJM199411103311902","article-title":"Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission","volume":"331","author":"Barrett","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2010.08.001_bib85","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.bbmt.2005.08.035","article-title":"The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: an evidence-based review","volume":"11","author":"Hahn","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib86","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1182\/blood-2005-12-4942","volume":"107","author":"Eapen","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib87","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2007-10-116582","volume":"111","author":"Goldstone","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib88","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1182\/blood.V95.5.1572.005k12_1572_1579","article-title":"Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial","volume":"95","author":"Locatelli","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib89","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1182\/blood.V77.7.1423.1423","article-title":"Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia","volume":"77","author":"Bacigalupo","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib90","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/blood.V88.1.41.41","article-title":"Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen","volume":"88","author":"Cardoso","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib91","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3109\/10428199809068567","article-title":"Donor lymphocyte infusion for the treatment of relapse after allogeneic hematopoietic stem cell transplantation","volume":"29","author":"Helg","year":"1998","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2010.08.001_bib92","first-page":"1553","article-title":"Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes","volume":"23","author":"Slavin","year":"1995","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib93","first-page":"109","article-title":"Donor leucocyte infusions after chemotherapy for patients relapsing with acute leukaemia following allogeneic BMT","volume":"11","author":"Szer","year":"1993","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib94","first-page":"331","article-title":"Complete remission following donor leukocyte infusion in ALL relapsing after haploidentical bone marrow transplantation","volume":"14","author":"Ferster","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib95","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1046\/j.1365-2141.1997.62650.x","article-title":"Donor lymphocyte infusion for childhood acute lymphoblastic leukaemia relapsing after bone marrow transplantation","volume":"97","author":"Atra","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib96","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-2257.1996.tb00737.x","article-title":"Abrupt cessation of immunosuppression in a patient with persistent acute lymphoblastic leukaemia following allogeneic transplantation","volume":"18","author":"Rymes","year":"1996","journal-title":"Clin Lab Haematol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib97","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1182\/blood.V84.11.3983a.bloodjournal84113983a","article-title":"Graft-versus-leukemia after second allogeneic bone marrow transplantation","volume":"84","author":"Aoki","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib98","first-page":"643","article-title":"[Graft-versus-leukemia effect induced by abrupt discontinuation of cyclosporine A following allogeneic bone marrow transplantation]","volume":"38","author":"Kanamori","year":"1997","journal-title":"Rinsho Ketsueki"},{"key":"10.1016\/j.bbmt.2010.08.001_bib99","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/sj.leu.2400644","article-title":"Infusion of donor-derived peripheral blood leukocytes after transplantation of cord blood progenitor cells can increase the graft-versus-leukaemia effect","volume":"11","author":"Locatelli","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.08.001_bib100","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/sj.bmt.1702555","article-title":"Donor leukocyte infusions in acute lymphocytic leukemia","volume":"26","author":"Collins","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib101","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1038\/sj.leu.2401581","article-title":"Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children","volume":"13","author":"Bader","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.08.001_bib102","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/sj.bmt.1700721","article-title":"Mixed hematopoietic chimerism after allogeneic bone marrow transplantation: the impact of quantitative PCR analysis for prediction of relapse and graft rejection in children","volume":"19","author":"Bader","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib103","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1200\/JCO.2004.05.198","article-title":"Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy?","volume":"22","author":"Bader","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib104","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/bmt.2008.259","article-title":"Donor lymphocyte infusions: the long and winding road: how should it be traveled?","volume":"42","author":"Tomblyn","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib105","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3324\/haematol.11960","article-title":"Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation","volume":"93","author":"Mohty","year":"2008","journal-title":"Haematology"},{"key":"10.1016\/j.bbmt.2010.08.001_bib106","first-page":"555","article-title":"Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study","volume":"88","author":"Martino","year":"2003","journal-title":"Haematology"},{"key":"10.1016\/j.bbmt.2010.08.001_bib107","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/sj.bmt.1704776","article-title":"Reduced-intensity stem-cell transplantation for adult acute lymphoblastic leukemia: a retrospective study of 33 patients","volume":"35","author":"Hamaki","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib108","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1182\/blood-2008-10-184093","article-title":"Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation","volume":"113","author":"Bachanova","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib109","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1182\/blood-2009-01-196303","article-title":"Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313","volume":"114","author":"Pulsipher","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2010.03.009","article-title":"Reduced intensity conditioning regimens for allogeneic transplantation in children with acute lymphoblastic leukemia","author":"Verneris","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib111","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1182\/blood-2003-03-0925","article-title":"Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia","volume":"102","author":"Kantarjian","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib112","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood-2003-06-2122","article-title":"Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia","volume":"103","author":"Jeha","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib113","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1016\/j.leukres.2008.12.005","article-title":"Nelarabine induced complete remission in an adult with refractory T-lineage acute lymphoblastic leukemia: a case report and review of the literature","volume":"33","author":"Sigalas","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2010.08.001_bib114","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood-2006-11-056754","article-title":"Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801","volume":"109","author":"DeAngelo","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib115","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1002\/cncr.24632","article-title":"Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia","volume":"115","author":"Thomas","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2010.08.001_bib116","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1182\/blood-2004-05-1746","article-title":"Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)","volume":"106","author":"Wassmann","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib117","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.leukres.2008.03.031","article-title":"Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib","volume":"33","author":"Tiribelli","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2010.08.001_bib118","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3324\/haematol.13353","article-title":"Effective use of imatinib-mesylate in the treatment of relapsed chronic myeloid leukemia after allogeneic transplantation","volume":"94","author":"Hayat","year":"2009","journal-title":"Haematology"},{"key":"10.1016\/j.bbmt.2010.08.001_bib119","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/bmt.2008.296","article-title":"Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL: impact of imatinib on relapse and survival","volume":"43","author":"Burke","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib120","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1182\/blood-2003-01-0150","article-title":"Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation","volume":"102","author":"Rezvani","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib121","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3109\/10428190009087014","article-title":"Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma","volume":"38","author":"Fowler","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2010.08.001_bib122","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/blood-2005-08-3373","article-title":"A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3\/CD28 costimulation","volume":"107","author":"Porter","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib123","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.4049\/jimmunol.156.12.4609","article-title":"Thymic-independent T cell regeneration occurs via antigen-driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing","volume":"156","author":"Mackall","year":"1996","journal-title":"J Immunol"},{"issue":"Suppl 2","key":"10.1016\/j.bbmt.2010.08.001_bib124","doi-asserted-by":"crossref","first-page":"14639","DOI":"10.1073\/pnas.0405730101","article-title":"Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes","volume":"101","author":"Rosenberg","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bbmt.2010.08.001_bib125","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/blood-2002-07-1989","article-title":"T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect","volume":"101","author":"Cooper","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib126","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-2005-872521","article-title":"Adoptive cellular immunotherapy with CD19-specific T cells","volume":"217","author":"Rossig","year":"2005","journal-title":"Klin Padiatr"},{"key":"10.1016\/j.bbmt.2010.08.001_bib127","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"Kohler","year":"1975","journal-title":"Nature"},{"key":"10.1016\/j.bbmt.2010.08.001_bib128","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/sj.leu.2403422","article-title":"Remission of adult acute lymphocytic leukaemia with alemtuzumab","volume":"18","author":"Laporte","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.08.001_bib129","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/00043426-200304000-00013","article-title":"Induction of long-term remission of a relapsed childhood B-acute lymphoblastic leukemia with rituximab chimeric anti-CD20 monoclonal antibody and autologous stem cell transplantation","volume":"25","author":"Corbacioglu","year":"2003","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib130","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/j.1365-2141.2008.07497.x","article-title":"Effectiveness of intrathecal rituximab in patients with acute lymphoblastic leukaemia relapsed to the CNS and resistant to conventional therapy","volume":"144","author":"Jaime-Perez","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib131","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/pbc.21753","article-title":"A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent\/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group","volume":"52","author":"Griffin","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bbmt.2010.08.001_bib132","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1200\/JCO.2007.15.3528","article-title":"Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children\u2019s Oncology Group Pilot Study","volume":"26","author":"Raetz","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib133","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2010.08.001_bib134","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1080\/10428190310001603948","article-title":"Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation","volume":"45","author":"Piccaluga","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2010.08.001_bib135","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1182\/blood-2003-05-1735","article-title":"Chimeric CD19 antibody mediates cytotoxic activity against leukemic blasts\u00a0with effector cells from pediatric patients who received T-cell-depleted allografts","volume":"103","author":"Lang","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib136","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/sj.leu.2402749","article-title":"Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin","volume":"17","author":"Zwaan","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.08.001_bib137","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1158\/1078-0432.CCR-09-2980","article-title":"Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial","volume":"16","author":"Wayne","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2010.08.001_bib138","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1182\/blood.V85.4.1122.bloodjournal8541122","article-title":"Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation","volume":"85","author":"Matthews","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib139","first-page":"717","article-title":"Denileukin diftitox for the treatment of cutaneous T-cell lymphoma","volume":"2","author":"Kaminetzky","year":"2008","journal-title":"Biologics"},{"key":"10.1016\/j.bbmt.2010.08.001_bib140","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.bbmt.2010.08.001_bib141","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/sj.leu.2403186","article-title":"Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity","volume":"18","author":"Mailander","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.08.001_bib142","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1182\/asheducation-2003.1.331","article-title":"Immunotherapy of hematologic malignancy","author":"Heslop","year":"2003","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.bbmt.2010.08.001_bib143","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/mt.sj.6300134","article-title":"Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules","volume":"15","author":"Suhoski","year":"2007","journal-title":"Mol Ther"},{"key":"10.1016\/j.bbmt.2010.08.001_bib144","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.exphem.2004.12.001","article-title":"Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia","volume":"33","author":"Haining","year":"2005","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib145","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.bbmt.2008.01.008","article-title":"Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome","volume":"14","author":"Armand","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib146","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/sj.bmt.1704600","article-title":"Reduced-intensity conditioning prior to allogeneic transplantation of hematopoietic stem cells: the need for T cells early after transplantation to induce a graft-versus-lymphoma effect","volume":"34","author":"Glass","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib147","first-page":"619","article-title":"Simultaneous infusion of high-dose cytosine arabinoside with cyclophosphamide followed by total body irradiation and marrow infusion for the treatment of patients with advanced hematological malignancy","volume":"6","author":"Petersen","year":"1988","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib148","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.bbmt.2004.05.008","article-title":"Graft-versus-lymphoma effects: clinical review, policy proposals, and immunobiology","volume":"9","author":"Grigg","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib149","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/sj.bmt.1700781","article-title":"Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effects","volume":"19","author":"Van Besien","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib150","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1046\/j.1365-2141.2000.02270-1.x","article-title":"Rituximab salvage following relapse after allogeneic bone marrow transplantation for non-Hodgkin\u2019s lymphoma","volume":"110","author":"Milojkovic","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib151","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1023\/A:1015463811683","article-title":"Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies?","volume":"22","author":"Selenko","year":"2002","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib152","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.ctrv.2009.07.004","article-title":"Clinical applications of rituximab in allogeneic stem cell transplantation: Anti-tumor and immunomodulatory effects","volume":"35","author":"Ratanatharathorn","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.bbmt.2010.08.001_bib153","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1007\/s00277-003-0696-z","article-title":"Treatment of lymphoma relapses after allogeneic hematopoietic stem cell transplantation with intensive chemotherapy followed by infusion of hematopoietic stem cell from the original donor","volume":"82","author":"Au","year":"2003","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib154","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.3109\/10428190903144642","article-title":"Fourth complete remission with immunosuppression withdrawal and irinotecan after both autologous and allogeneic transplants for diffuse large B cell lymphoma","volume":"50","author":"Gupta","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2010.08.001_bib155","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s12185-008-0174-4","article-title":"Involved field radiation therapy and donor lymphocyte infusion for relapsed or refractory non-Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation","volume":"88","author":"Behre","year":"2008","journal-title":"Int J Hematol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib156","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1182\/blood-2008-07-168468","article-title":"CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation","volume":"113","author":"Bashey","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib157","article-title":"Thalidomide induced remission of refractory diffuse large B-Cell Lymphoma post-allogeneic SCT","volume":"91","author":"Tueger","year":"2006","journal-title":"Haematology"},{"key":"10.1016\/j.bbmt.2010.08.001_bib158","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1046\/j.1365-2141.2003.04082.x","article-title":"Complete remission of tumour with interleukin 2 therapy in a patient with non-Hodgkin\u2019s lymphoma post allogeneic bone marrow transplant associated with polyclonal T-cell bone marrow lymphocytosis","volume":"120","author":"Kiss","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib159","first-page":"155","article-title":"[Remission induction of refractory diffuse large B-cell lymphoma with allogeneic peripheral blood stem cell transplantation followed by interferon-alpha and donor lymphocyte infusion]","volume":"45","author":"Kawano","year":"2004","journal-title":"Rinsho Ketsueki"},{"key":"10.1016\/j.bbmt.2010.08.001_bib160","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S1083-8791(00)70009-7","article-title":"Second allogeneic transplantation after failure of first autologous transplantation","volume":"3","author":"Radich","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib161","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2004-01-0231","article-title":"Myeloablative allogeneic hematopoietic stem cell transplantation in patients who relapse after autologous stem cell transplantation for lymphoma: a report of the international bone marrow transplant registry","volume":"104","author":"Freytes","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib162","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1182\/blood-2008-01-136242","article-title":"Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab","volume":"111","author":"Khouri","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib163","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1200\/JCO.2007.11.5477","article-title":"Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin\u2019s lymphoma","volume":"26","author":"Rezvani","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib164","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1182\/blood-2002-03-0701","article-title":"Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders","volume":"100","author":"Perez-Simon","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib165","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2004-03-1105","article-title":"Outcome following alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant regimen for relapsed and refractory non-Hodgkin\u2019s lymphoma (NHL)","volume":"104","author":"Morris","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib166","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2141.2008.07067.x","article-title":"Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma","volume":"141","author":"Ingram","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib167","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1200\/JCO.2008.17.3328","article-title":"Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin\u2019s lymphoma","volume":"27","author":"Thomson","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib168","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bbmt.2009.09.002","article-title":"Low non-relapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma: Report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire","volume":"16","author":"Sirvent","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib169","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/annonc\/mdn404","article-title":"Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation","volume":"19","author":"Bishop","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib170","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1182\/blood-2004-06-2275","article-title":"Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma","volume":"104","author":"Maris","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib171","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1200\/JCO.2003.05.501","article-title":"Nonablative allogeneic stem-cell transplantation for advanced\/recurrent mantle-cell lymphoma","volume":"21","author":"Khouri","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib172","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1182\/blood-2008-10-184200","article-title":"Mature results of the M.D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma","volume":"113","author":"Tam","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib173","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1080\/10428190903026518","article-title":"Autologous and allogeneic stem cell transplantation: rising therapeutic promise for mantle cell lymphoma","volume":"50","author":"Tam","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2010.08.001_bib174","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.bbmt.2008.04.014","article-title":"A retrospective analysis of allogeneic hematopoietic stem cell transplantation for adult T cell leukemia\/lymphoma (ATL): clinical impact of graft-versus-leukemia\/lymphoma effect","volume":"14","author":"Shiratori","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib175","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1365-2141.2008.07212.x","article-title":"Sustained response after reduced-intensity conditioning allogeneic stem cell transplantation for patients with relapsed peripheral T-cell non-Hodgkin lymphoma","volume":"142","author":"de Lavallade","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib176","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.bbmt.2008.01.002","article-title":"Allogeneic hematopoietic stem cell transplantation for peripheral T cell lymphomas; evidence of graft-versus-T cell lymphoma effect","volume":"14","author":"Hamadani","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib177","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1200\/JCO.2008.20.4628","article-title":"Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation","volume":"27","author":"Kyriakou","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib178","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1182\/blood-2007-07-098483","article-title":"Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia","volume":"111","author":"Sorror","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib179","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/blood-2007-03-078592","article-title":"Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"110","author":"Kahl","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib180","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1200\/JCO.1996.14.2.572","article-title":"Bone marrow transplants from HLA-identical siblings in advanced Hodgkin\u2019s disease","volume":"14","author":"Gajewski","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib181","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1200\/JCO.1993.11.12.2342","article-title":"Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin\u2019s disease: the 21-year Seattle experience","volume":"11","author":"Anderson","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib182","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/blood.V77.3.649.649","article-title":"Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation","volume":"77","author":"Jones","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib183","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1200\/JCO.2001.19.23.4314","article-title":"Long-term results of blood and marrow transplantation for Hodgkin\u2019s lymphoma","volume":"19","author":"Akpek","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib184","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1016\/S0140-6736(05)66659-7","article-title":"Clinical evidence of a graft-versus-Hodgkin\u2019s-lymphoma effect after reduced-intensity allogeneic transplantation","volume":"365","author":"Peggs","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2010.08.001_bib185","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/sj.bmt.1704942","article-title":"Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin\u2019s disease: low transplant-related mortality and impact of intensity of conditioning regimen","volume":"35","author":"Anderlini","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib186","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.bbmt.2005.09.009","article-title":"Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a Spanish prospective cooperative protocol","volume":"12","author":"Alvarez","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib187","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1038\/sj.leu.2404822","article-title":"Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome","volume":"21","author":"Corradini","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.08.001_bib188","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1182\/blood-2005-09-3827","article-title":"Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma","volume":"107","author":"Majhail","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib189","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/sj.bmt.1703895","article-title":"\u201cGVHD\u201d: graft-versus-host disease or graft-versus-Hodgkin\u2019s disease? An old acronym with new meaning","volume":"31","author":"Porter","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib190","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3324\/haematol.13441","article-title":"Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin\u2019s lymphoma: identification of prognostic factors predicting outcome","volume":"94","author":"Robinson","year":"2009","journal-title":"Haematology"},{"key":"10.1016\/j.bbmt.2010.08.001_bib191","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2003-05-1513","article-title":"Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses","volume":"103","author":"Peggs","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib192","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3324\/haematol.11828","article-title":"Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin\u2019s lymphoma: the updated M.D. Anderson Cancer Center experience","volume":"93","author":"Anderlini","year":"2008","journal-title":"Haematology"},{"key":"10.1016\/j.bbmt.2010.08.001_bib193","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1365-2141.2007.06759.x","article-title":"Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes","volume":"139","author":"Peggs","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib194","first-page":"86","article-title":"Epstein-Barr viral DNA in tissues of Hodgkin\u2019s disease","volume":"129","author":"Weiss","year":"1987","journal-title":"Am J\u00a0Pathol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib195","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1182\/blood.V78.5.1162.1162","article-title":"Activation of Epstein-Barr virus replication in Hodgkin and Reed-Sternberg cells","volume":"78","author":"Pallesen","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib196","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1182\/blood.V90.4.1664","article-title":"Immunohistochemical detection of the Epstein-Barr virus-encoded latent membrane protein 2A in Hodgkin\u2019s disease and infectious mononucleosis","volume":"90","author":"Niedobitek","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib197","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.1073\/pnas.88.11.4766","article-title":"Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells","volume":"88","author":"Herbst","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bbmt.2010.08.001_bib198","series-title":"The Non-Hodgkin\u2019s Lymphomas","first-page":"309","article-title":"Epstein-Barr virus and non-Hodgkin\u2019s lymphomas","author":"Niedobitek","year":"1997"},{"key":"10.1016\/j.bbmt.2010.08.001_bib199","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1084\/jem.20040890","article-title":"Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin\u2019s disease","volume":"200","author":"Bollard","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.bbmt.2010.08.001_bib200","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1182\/blood-2007-05-091280","article-title":"Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer","volume":"110","author":"Bollard","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib201","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1182\/blood-2006-11-059139","article-title":"Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease","volume":"110","author":"Savoldo","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib202","author":"Kroger","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib203","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1200\/JCO.2007.15.4757","article-title":"Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after\u00a0nonmyeloablative conditioning","volume":"26","author":"Sorror","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib204","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood-2005-08-3372","article-title":"Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study","volume":"107","author":"Delgado","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib205","first-page":"28","article-title":"Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival","volume":"32","author":"Khouri","year":"2004","journal-title":"Exp\u00a0Hematol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib206","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1200\/JCO.2003.12.011","article-title":"Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group","volume":"21","author":"Schetelig","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib207","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.bbmt.2006.06.004","article-title":"Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia","volume":"12","author":"Brown","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib208","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.3324\/haematol.11185","article-title":"Allogeneic transplantation in lymphoma: current status","volume":"92","author":"Schmitz","year":"2007","journal-title":"Haematology"},{"key":"10.1016\/j.bbmt.2010.08.001_bib209","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2010-03-275420","article-title":"Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia:long-term clinical and MRD results of the GCLLSG CLL3X trial","author":"Dreger","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib210","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.bbmt.2008.09.001","article-title":"The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia","volume":"14","author":"Delgado","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib211","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1200\/JCO.2005.04.569","article-title":"Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia","volume":"23","author":"Sorror","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib212","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1038\/sj.leu.2404838","article-title":"Characterization of graft-versus-leukemia responses in patients treated for advanced chronic lymphocytic leukemia with donor lymphocyte infusions after in vitro T-cell depleted allogeneic stem cell transplantation following reduced-intensity conditioning","volume":"21","author":"Hoogendoorn","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.08.001_bib213","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/leu.2008.96","article-title":"Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial","volume":"22","author":"Ritgen","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.08.001_bib214","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1182\/blood-2005-09-3634","article-title":"Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia","volume":"107","author":"Moreno","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib215","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/sj.bmt.1703810","article-title":"Allogeneic transplantation for multiple myeloma: late relapse may occur as localised lytic lesion\/plasmacytoma despite ongoing molecular remission","volume":"31","author":"Byrne","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib216","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/bmt.2008.185","article-title":"Minimal residual disease diagnostics in myeloid malignancies in the post transplant period","volume":"42","author":"Bacher","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib217","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1038\/sj.leu.2404928","article-title":"Genetically identical twin transplantation for chronic lymphocytic leukemia","volume":"21","author":"Pavletic","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.08.001_bib218","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/j.1365-2141.2007.06862.x","article-title":"Bioethical considerations of monoclonal B-cell lymphocytosis: donor transfer after haematopoietic stem cell transplantation","volume":"139","author":"Hardy","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib219","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1053\/j.seminhematol.2004.05.002","article-title":"Perspectives on familial chronic lymphocytic leukemia: genes and the environment","volume":"41","author":"Caporaso","year":"2004","journal-title":"Semin Hematol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib220","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1182\/blood.V100.2.635","article-title":"Monoclonal B lymphocytes with the characteristics of \u201cindolent\u201d chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts","volume":"100","author":"Rawstron","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib221","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2141.2005.05550.x","article-title":"Diagnostic criteria for monoclonal B-cell lymphocytosis","volume":"130","author":"Marti","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib222","first-page":"1","article-title":"B-cell monoclonal lymphocytosis and B-cell abnormalities in the setting of familial B-cell chronic lymphocytic leukemia","volume":"52","author":"Marti","year":"2003","journal-title":"Cytometry"},{"key":"10.1016\/j.bbmt.2010.08.001_bib223","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1182\/blood-2002-03-0892","article-title":"Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion","volume":"100","author":"Rawstron","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib224","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1182\/blood-2005-05-1778","article-title":"Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia","volume":"106","author":"Gribben","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib225","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.2005.08.136","article-title":"Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with\u00a0nonmyeloablative conditioning","volume":"23","author":"Baron","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib226","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.leu.2402905","article-title":"Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell\u00a0transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning","volume":"17","author":"Dreger","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.08.001_bib227","first-page":"669","article-title":"Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia","volume":"18","author":"Rondon","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib228","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1053\/bbmt.1999.v5.pm10465105","article-title":"Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions","volume":"5","author":"Porter","year":"1999","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib229","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.bbmt.2005.11.520","article-title":"Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions","volume":"12","author":"Huff","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib230","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood-2003-07-2344","article-title":"Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning","volume":"103","author":"Bethge","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib231","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.bmt.1705074","article-title":"Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation","volume":"36","author":"Russell","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib232","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bbmt.2007.04.013","article-title":"High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma","volume":"14","author":"Bloor","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib233","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00262-005-0015-8","article-title":"Immune defects in patients with chronic lymphocytic leukemia","volume":"55","author":"Ravandi","year":"2006","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.bbmt.2010.08.001_bib234","doi-asserted-by":"crossref","first-page":"5921","DOI":"10.4049\/jimmunol.159.12.5921","article-title":"Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells","volume":"159","author":"Levine","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib235","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/bmt.2008.323","article-title":"Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 \u00d7 anti-CD20 antibody and donor lymphocyte infusion","volume":"43","author":"Buhmann","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib236","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2010-01-265041","article-title":"Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib237","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/mt.2010.31","article-title":"Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial","volume":"18","author":"Brentjens","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.bbmt.2010.08.001_bib238","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.bbmt.2010.08.001_bib239","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1158\/0008-5472.CAN-09-3845","article-title":"Combining CD19 redirection and alloanergization to generate tumor-specific human T\u00a0cells for allogeneic cell therapy of B-cell malignancies","volume":"70","author":"Davies","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2010.08.001_bib240","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s00262-008-0561-y","article-title":"Development of a dendritic cell-based vaccine for chronic lymphocytic leukemia","volume":"57","author":"Palma","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.bbmt.2010.08.001_bib241","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/leu.2008.29","article-title":"Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response","volume":"22","author":"Hus","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.08.001_bib242","first-page":"1653","article-title":"Cancer vaccines for patients with acute myeloid leukemia\u2014definition of leukemia-associated antigens and current clinical protocols targeting these antigens","volume":"91","author":"Greiner","year":"2006","journal-title":"Haematology"},{"key":"10.1016\/j.bbmt.2010.08.001_bib243","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1080\/10428190500464062","article-title":"Survivin-derived peptide epitopes and their role for induction of antitumor immunity in hematological malignancies","volume":"47","author":"Friedrichs","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2010.08.001_bib244","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1182\/blood-2002-08-2554","article-title":"Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells","volume":"102","author":"Schmidt","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib245","doi-asserted-by":"crossref","first-page":"7955","DOI":"10.1016\/j.vaccine.2007.08.050","article-title":"Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models","volume":"25","author":"Zhu","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.bbmt.2010.08.001_bib246","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1080\/1042819021000006547","article-title":"Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia","volume":"43","author":"Keating","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2010.08.001_bib247","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/sj.thj.6200325","article-title":"Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia","volume":"5","author":"Thornton","year":"2004","journal-title":"Hematol J"},{"key":"10.1016\/j.bbmt.2010.08.001_bib248","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.V84.9.3148.3148","article-title":"p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies","volume":"84","author":"Wattel","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib249","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1182\/blood.V85.6.1580.bloodjournal8561580","article-title":"p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias","volume":"85","author":"Dohner","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib250","first-page":"36","article-title":"Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab","volume":"63","author":"Byrd","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2010.08.001_bib251","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1200\/JCO.2008.16.2982","article-title":"Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis","volume":"26","author":"Schetelig","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib252","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1200\/JCO.2005.04.531","article-title":"Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia","volume":"23","author":"Moreno","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib253","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1080\/10428190701573257","article-title":"The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy","volume":"48","author":"Tam","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2010.08.001_bib254","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1002\/cncr.20264","article-title":"Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia","volume":"100","author":"Tsimberidou","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2010.08.001_bib255","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1200\/JCO.2001.19.5.1414","article-title":"Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia","volume":"19","author":"O\u2019Brien","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib256","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1200\/JCO.2005.12.516","article-title":"Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia","volume":"23","author":"Wierda","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib257","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1200\/JCO.2003.08.100","article-title":"Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia","volume":"21","author":"Weiss","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib258","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.2005.04.3836","article-title":"Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia","volume":"24","author":"Lamanna","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib259","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1200\/JCO.2008.18.7252","article-title":"Bendamustine: rebirth of an old drug","volume":"27","author":"Cheson","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib260","doi-asserted-by":"crossref","first-page":"6907","DOI":"10.1158\/1078-0432.CCR-08-0388","article-title":"Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling","volume":"14","author":"Roue","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2010.08.001_bib261","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3109\/10428190903586318","article-title":"The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant","volume":"51","author":"Alousi","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2010.08.001_bib262","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.seminhematol.2005.10.001","article-title":"Lenalidomide and thalidomide: mechanisms of action\u2014similarities and differences","volume":"42","author":"Anderson","year":"2005","journal-title":"Semin Hematol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib263","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.1200\/JCO.2005.05.0401","article-title":"Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study","volume":"24","author":"Chanan-Khan","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib264","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1182\/blood-2007-12-130120","article-title":"Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia","volume":"111","author":"Ferrajoli","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib265","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1200\/JCO.2007.13.9709","article-title":"Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia","volume":"26","author":"Andritsos","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib266","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1182\/blood-2004-01-0039","article-title":"Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas","volume":"104","author":"Teeling","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib267","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2007-09-111781","article-title":"Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study","volume":"111","author":"Coiffier","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib268","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2141.2010.08251.x","article-title":"Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia","author":"Mussai","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib269","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1200\/JCO.2006.07.1191","article-title":"Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia","volume":"25","author":"O\u2019Brien","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib270","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.1200\/JCO.2008.18.3160","article-title":"Exploiting the apoptotic route for cancer treatment: a single hit will rarely result in a home run","volume":"26","author":"de Vries","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib271","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nrc2293","article-title":"Survivin, cancer networks and pathway-directed drug discovery","volume":"8","author":"Altieri","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bbmt.2010.08.001_bib272","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1182\/blood-2007-03-082024","article-title":"Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines","volume":"111","author":"Pathan","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib273","doi-asserted-by":"crossref","first-page":"14a","DOI":"10.1182\/blood.V108.11.32.32","article-title":"Comparison of results from a phase 1\/2 study of lumiliximab (anti-CD23) in combination with FCR for patients with relapsed CLL with published FCR results","volume":"108","author":"Byrd","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib274","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1182\/blood-2008-05-157131","article-title":"Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers","volume":"112","author":"Pepper","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib275","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.exphem.2004.03.006","article-title":"Functional evaluation of the role of inhibitor of apoptosis proteins in chronic lymphocytic leukemia","volume":"32","author":"Schliep","year":"2004","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib276","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2006-05-020735","article-title":"Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia","volume":"109","author":"Byrd","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib277","doi-asserted-by":"crossref","first-page":"6012","DOI":"10.1200\/JCO.2009.22.6944","article-title":"Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease","volume":"27","author":"Lin","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib278","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.3324\/haematol.13311","article-title":"B-cell involvement in chronic graft-versus-host disease","volume":"93","author":"Kapur","year":"2008","journal-title":"Haematology"},{"key":"10.1016\/j.bbmt.2010.08.001_bib279","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.clim.2008.01.011","article-title":"Rituximab-induced B cell depletion in\u00a0autoimmune diseases: potential effects on T cells","volume":"127","author":"Liossis","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib280","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1200\/JCO.1999.17.1.208","article-title":"Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells","volume":"17","author":"Corradini","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib281","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1200\/JCO.2000.18.11.2273","article-title":"Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma","volume":"18","author":"Martinelli","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib282","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1182\/blood.V88.7.2787.bloodjournal8872787","article-title":"Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome","volume":"88","author":"Bensinger","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib283","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1365-2141.2004.05330.x","article-title":"Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning\u2014evidence for a superior outcome using melphalan combined with total body irradiation","volume":"128","author":"Hunter","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib284","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/sj.bmt.1704049","article-title":"Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I\/II study of the German Study-group Multiple Myeloma (DSMM)","volume":"31","author":"Kroger","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib285","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1182\/blood-2006-07-036848","article-title":"Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning","volume":"109","author":"Crawley","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib286","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/sj.leu.2404085","article-title":"Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients","volume":"20","author":"Perez-Simon","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.08.001_bib287","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/sj.bmt.1705982","article-title":"Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome","volume":"41","author":"Minnema","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib288","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196","article-title":"Graft-versus-myeloma effect: proof of principle","volume":"87","author":"Tricot","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib289","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1182\/blood-2003-11-3862","article-title":"The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma","volume":"103","author":"Lokhorst","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib290","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/sj.bmt.1702685","article-title":"Donor leukocyte infusions for multiple myeloma","volume":"26","author":"Salama","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib291","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/S0140-6736(96)90871-5","article-title":"Graft-versus-myeloma effect in two cases","volume":"96","author":"Verdonck","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2010.08.001_bib292","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/sj.leu.2400546","article-title":"Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect","volume":"11","author":"Bertz","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.08.001_bib293","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1182\/blood.V90.10.4206","article-title":"Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation","volume":"90","author":"Lokhorst","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib294","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/sj.leu.2403252","article-title":"Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma","volume":"18","author":"Ayuk","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.08.001_bib295","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1182\/blood.V98.4.934","article-title":"T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect","volume":"98","author":"Alyea","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib296","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/bbmt.2003.50009","article-title":"Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity","volume":"9","author":"Peggs","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib297","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1046\/j.1365-2141.2001.02599.x","article-title":"Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma","volume":"112","author":"Kroger","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib298","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/sj.bmt.1705393","article-title":"Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma","volume":"37","author":"van de Donk","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib299","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1182\/blood-2007-08-104471","article-title":"A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique","volume":"111","author":"Mielke","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib300","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood.V98.1.210","article-title":"Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma","volume":"98","author":"Davies","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib301","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1182\/blood-2004-05-2031","article-title":"Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma","volume":"104","author":"Kroger","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib302","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/sj.bmt.1704756","article-title":"Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myelome (IFM) and the Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC)","volume":"35","author":"Mohty","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib303","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/bmt.2009.155","article-title":"Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells","volume":"45","author":"Lioznov","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib304","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/leu.2008.247","article-title":"Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells","volume":"23","author":"Minnema","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.08.001_bib305","article-title":"Bortezomib inhibits T cell proliferation","volume":"102","author":"Kaufman","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib306","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1073\/pnas.0401563101","article-title":"Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib","volume":"101","author":"Sun","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bbmt.2010.08.001_bib307","first-page":"1230","article-title":"A multi-institutional study of extracorporeal photoimmune therapy with UVADEX(R) for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation","volume":"104","author":"Shaughnessy","year":"2004","journal-title":"Blood (ASH Annu Meet Abstr.)"},{"key":"10.1016\/j.bbmt.2010.08.001_bib308","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3324\/haematol.12184","article-title":"High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma","volume":"93","author":"El-Cheikh","year":"2008","journal-title":"Haematology"},{"key":"10.1016\/j.bbmt.2010.08.001_bib309","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.exphem.2006.02.020","article-title":"Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status","volume":"34","author":"Kroger","year":"2006","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib310","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1182\/blood-2005-11-4449","article-title":"Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma","volume":"107","author":"van de Donk","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib311","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/sj.bmt.1701403","article-title":"Adjuvant alpha-interferon improves complete remission rates following allogeneic transplantation for multiple myeloma","volume":"22","author":"Byrne","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib312","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(95)90757-2","article-title":"Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor","volume":"345","author":"Kwak","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2010.08.001_bib313","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/sj.bmt.1705057","article-title":"Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma","volume":"36","author":"Neelapu","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib314","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1182\/blood-2006-04-014480","article-title":"Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation","volume":"109","author":"Atanackovic","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib315","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1097\/CJI.0b013e318158fcff","article-title":"Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma","volume":"30","author":"Szmania","year":"2007","journal-title":"J Immunother"},{"key":"10.1016\/j.bbmt.2010.08.001_bib316","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1365-2141.2005.05513.x","article-title":"Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma","volume":"129","author":"Kroger","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib317","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1182\/blood-2004-11-4463","article-title":"Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor","volume":"105","author":"Bellucci","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib318","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1182\/blood-2002-02-0506","article-title":"The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation","volume":"100","author":"Marks","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib319","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/sj.bmt.1704290","article-title":"Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation","volume":"32","author":"Mandigers","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.08.001_bib320","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1365-2141.2008.07349.x","article-title":"Allogeneic transplantation for Hodgkin lymphoma","volume":"143","author":"Peggs","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2010.08.001_bib321","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1182\/blood-2003-12-4321","article-title":"Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR","volume":"104","author":"Ritgen","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.08.001_bib322","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1182\/asheducation-2005.1.292","article-title":"Salvage therapy for CLL and the role of stem cell transplantation","author":"Gribben","year":"2005","journal-title":"Hematology Am Soc Hematol Educ Program"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879110003393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879110003393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:37:41Z","timestamp":1761057461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879110003393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":322,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S1083879110003393"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2010.08.001","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2010.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}